SEDICO Pharmaceutical

What SEDICO Pharmaceutical does

SEDICO Pharmaceutical is an Egyptian privately-held pharmaceutical manufacturer founded in 1990 and headquartered in the 1st Industrial Zone of 6th of October City, with a secondary scientific office in Maadi. The company operates a broad generics and licensed-products portfolio spanning 17 therapeutic areas — including anti-infectives, cardiovascular, musculoskeletal, respiratory, gastrointestinal, dermatologicals, and systemic hormones — and a growing specialty/biologic segment comprising recombinant human insulin (BIO R, MIX, NPH), Somatropin (human growth hormone), Epoetin (erythropoietin), and Filgrastim (G-CSF). SEDICO also maintains a nutritional and herbal supplements line and an oncology injectables portfolio that includes Gemcitabine, Paclitaxel, Methotrexate, Irinotecan, Oxaliplatin, and Epirubicin across multiple dosage strengths, manufactured in dosage forms ranging from tablets, capsules, and syrups to ampoules, vials, suppositories, gels, and creams.

The company monetizes through one-time sales of its pharmaceutical products via a sales-led go-to-market model, distributing through regional pharmaceutical wholesalers and healthcare supply chains to hospitals, pharmacies, and healthcare providers in Egypt and 11+ export markets including Yemen, Oman, Kuwait, Bahrain, Sudan, Uganda, Tanzania, Ethiopia, Tajikistan, and CIS countries. SEDICO holds licensing arrangements (e.g., with F. Trenka for Eucarbon), maintains pharmacovigilance integration with the Egyptian Drug Authority's EPVC system, and pursues international growth via exhibitions such as Arab Health, CPhI, WHX Dubai, and Africa Health ExCon. Leadership is headed by Prof. Dr. Fathy Ibrahim as Chairman & CEO (appointed January 2025), and the company was recognized by the Egyptian Drug Authority in 2025 for export excellence.

Name

SEDICO Pharmaceutical

Legal name

SEDICO

Website

https://sedicopharma.com

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

SEDICO Pharmaceutical is a privately-held Egyptian generics and biologics manufacturer producing 100+ pharmaceutical products across 17 therapeutic areas — including insulin, oncology injectables, and supplements — sold to hospitals, pharmacies, and healthcare providers in Egypt and 11+ export markets across MEA and CIS.

Ownership category

akta.pro rank

Headquarters

HQ city

6 October City

HQ country

Egypt

HQ region

Africa

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: SEDICO generates revenue through the manufacture and sale of generic pharmaceutical products across 17 therapeutic areas. Products are sold to healthcare providers, pharmacies, hospitals, and through regional distribution networks across Middle East, Africa, and CIS markets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

SEDICO Pharmaceutical is an Egyptian pharmaceutical manufacturer that produces and distributes a broad portfolio of generic and branded pharmaceutical products spanning 17 therapeutic areas. The company manufactures formulations including tablets, capsules, syrups, injectable vials and ampoules, gels, creams, suppositories, and sachets, covering anti-neoplastics, antibiotics, recombinant biologics (insulin, Filgrastim, Somatropin, Epoetin), NSAIDs, cardiovascular, respiratory, gastrointestinal, antidiabetic, antifungal, antiviral, anesthetic, and herbal/nutritional supplement products. Products are supplied to healthcare providers, pharmacies, and hospitals across Egypt, the Middle East, Africa, and CIS markets.

Product overview

SEDICO Pharmaceutical is an Egyptian pharmaceutical company offering a diverse portfolio of generic and branded pharmaceutical products across 17 therapeutic areas. The portfolio includes RHEUMARENE line (Diclofenac Sodium in gel, tablet, and injectable forms), musculoskeletal agents like CYCLOSED and IBUPROFEN, a comprehensive anti-infectives range including BIOMOX, MAGNABIOTIC, FLUCAMOX, and ULTRACILLIN antibiotics, oncology products such as Gemcitabine, Paclitaxel, Methotrexate, Irinotecan, Oxaliplatin, and Epirubicin in multiple dosage strengths, cardiovascular medications including LIPONA (Atorvastatin), Furosemide diuretics, and cardiovascular supplements like OMEGA 3 PLUS, diabetes management products including DIABRIDE (Glimepride) and INSULIN H series, respiratory medications like AIRONYL (Terbutaline), SEDOKAST (Montelukast), and mucolytics, gastrointestinal products such as OMEPAK (Omeprazole), FAMOTAK (Famotidine), and VISCERALGINE antispasmodics, herbal and nutritional supplements including SILYMARIN PLUS, ROYAL VIT G, and CALCIUM EFFERVESCENT, reproductive health products, and hospital solutions. The company manufactures in multiple dosage forms including tablets, capsules, syrups, suspensions, injectable ampoules and vials, topical gels and creams, sachets, and inhalers.

Differentiator

Problem solved

Functional benefit

Brands

• SEDICO Health: Health information portal providing educational content about pharmaceutical products and medical conditions

Products and services

• CYCLOSED Muscle relaxant medication containing Cyclobenzaprine, available as tablets, for musculoskeletal conditions, for healthcare providers and pharmacies.
• CELOXIB 200 MG NSAID containing Celecoxib in capsule form for pain and inflammation relief, for healthcare providers and pharmacies.
• INESTAFENAC NSAID containing Diclofenac potassium in sachet form for pain and inflammation, for healthcare providers and pharmacies.
• RHEUMARENE 1% Topical NSAID gel containing Diclofenac Sodium for local pain relief, for healthcare providers and pharmacies.
• RHEUMARENE 50 MG NSAID tablet containing Diclofenac Sodium for pain and inflammation management, for healthcare providers and pharmacies.
• RHEUMARENE 75 MG NSAID injectable solution containing Diclofenac Sodium in ampoule form, for healthcare providers and pharmacies.
• IBUPROFEN Syrup NSAID analgesic and antipyretic medication in syrup form, for healthcare providers and pharmacies.
• IBUPROFEN 400 MG NSAID analgesic and antipyretic medication in tablet form, for healthcare providers and pharmacies.
• FAULCURIUM 25 MG/2.5 ML Neuromuscular blocking agent containing Atracurium besylate in injectable form, for hospitals and surgical use.
• FAULCURIUM 50 MG/5 ML

Quantifiable outcome

• Manufacturing presence in 11+ countries across Middle East, Africa, and CIS regions

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Cipla: Indian multinational with deep emerging-markets generics portfolio, including oncology, respiratory, and biosimilars. Competes with SEDICO on price in African tenders and increasingly in MEA markets.
• Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer with broad generics portfolio across MENA markets, including injectables and biologics. Comparable on regional manufacturing footprint and export distribution model.
• Hikma Pharmaceuticals: Jordan-headquartered multinational with deep MENA generics and injectables footprint, including biosimilars and oncology. Overlaps with SEDICO in regional tenders but operates at significantly greater scale and geographic breadth.
• Aspen Pharmacare: South African-headquartered generics and specialty pharma group with strong presence across African and emerging markets, including oncology and biologics. Competes with SEDICO for African tender wins.

Direct peers

• EIPICO (Egyptian International Pharmaceutical Industries Company): One of Egypt's largest generic pharmaceutical manufacturers headquartered near Cairo with a comparable multi-therapeutic-area portfolio and broad MEA export reach. Directly competes with SEDICO in Egyptian tenders and regional generics distribution.
• Eva Pharma: Egyptian pharmaceutical manufacturer with a similarly broad generics portfolio across multiple therapeutic areas, including oncology, antibiotics, and biologics. Competes head-to-head with SEDICO in Egyptian and African markets.
• Amoun Pharmaceutical: Egyptian pharmaceutical company producing human and veterinary generics across multiple therapeutic categories with regional export presence. Closely comparable on portfolio breadth and Egyptian-market positioning.
• Pharco Pharmaceuticals: Egypt's largest pharmaceutical manufacturer by volume, with a deep multi-therapeutic generics portfolio and significant MENA/Africa exports. Direct competitor for SEDICO across retail and tender channels.

Regional players

• Tabuk Pharmaceuticals: Saudi pharmaceutical company producing generics and specialty products for MENA markets with growing export focus. Overlaps with SEDICO on therapeutic breadth, though concentrated in Gulf rather than African/CIS geographies.
• SPIMACO Addwaeih: Saudi Arabian pharmaceutical manufacturer with broad generics portfolio and growing biosimilars capability. Comparable on multi-therapeutic-area model and MENA distribution, primarily serving Gulf markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/SEDICOPharma
• Facebookfacebook.com/SEDICOPharma
• LinkedInlinkedin.com/company/sedico-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SEDICO Pharmaceutical